文献速递肺结节与肺癌

每日一次赛沃替尼治疗中国MET外显子14跳跃突变肺肉瘤样癌及其他非小细胞肺癌:多中心、单臂、开放标签、2期研究

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
PubMed 文献 · Lancet Respir Med · 2021-06-21

该研究为多中心单臂开放标签2期试验,纳入70例METex14跳跃突变肺肉瘤样癌或其他NSCLC患者,每日口服赛沃替尼。所有患者发生治疗相关不良事件,≥3级发生率为46%,安全性可接受。

要点

  • 赛沃替尼在METex14跳跃突变肺肉瘤样癌及其他NSCLC中显示 promising 抗肿瘤活性。
  • 安全性可接受,≥3级治疗相关不良事件发生率46%,常见转氨酶升高和周围水肿。

核心结论

  • 赛沃替尼在METex14跳跃突变肺肉瘤样癌及其他NSCLC亚型中显示出有前景的活性和可接受的安全性。

研究设计与样本

  • 多中心、单臂、开放标签、2期研究,在中国32家医院开展。
  • 纳入70例METex14跳跃突变阳性、MET抑制剂初治的局部晚期或转移性肺肉瘤样癌或其他NSCLC患者。
  • 患者每日口服赛沃替尼600 mg(体重≥50 kg)或400 mg(体重<50 kg),直至疾病进展、死亡、不可耐受毒性等。
  • 主要终点为独立评审委员会(IRC)评估的客观缓解率,在肿瘤反应可评估集(61例)中评估,并在全分析集(70例)中做敏感性分析。

主要发现

  • 所有70例患者报告至少1例治疗相关不良事件。
  • ≥3级治疗相关不良事件发生于32例(46%)患者,最常见为天冬氨酸氨基转移酶升高(9例)、丙氨酸氨基转移酶升高(7例)和外周水肿(6例)。
  • 治疗相关严重不良事件发生于17例(24%)患者,最常见为肝功能异常(3例)和过敏反应(2例)。
  • 1例肺肉瘤样癌患者死于肿瘤溶解综合征,研究者评估可能与赛沃替尼相关。

临床怎么用

  • 赛沃替尼可作为METex14跳跃突变的肺肉瘤样癌及其他NSCLC患者的一种新型治疗选择。
  • 治疗期间需监测肝酶升高和外周水肿等不良事件。

局限性

  • 单臂设计,无对照,结论需进一步随机研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Savolitinib is a selective MET tyrosine-kinase inhibitor. We investigated the activity and safety of savolitinib in patients with pulmonary sarcomatoid carcinoma and other non-small-cell lung cancer (NSCLC) subtypes positive for MET exon 14 skipping alterations (METex14-positive). METHODS: We did a multicentre, single-arm, open-label, phase 2 study across 32 hospitals in China. Eligible patients were 18 years or older with locally advanced or metastatic METex14-positive pulmonary sarcomatoid carcinoma or other NSCLC subtypes, had either presented with disease progression or toxicity intolerance towards one or more standard treatments or were deemed clinically unsuitable for standard treatment, were MET inhibitor-naive, and had measurable disease. Patients received either 600 mg (bodyweight ≥50 kg) or 400 mg (bodyweight <50 kg) of oral savolitinib once daily until disease progression, death, intolerable toxicity, initiation of other anti-tumour therapy, non-compliance, patient withdrawal, or patient discontinuation. Radiographic tumour evaluation was done at baseline, every 6 weeks within 1 year of the first dose, and every 12 weeks thereafter. The primary endpoint was objective response rate, defined as the proportion of patients with confirmed complete or partial responses by independent review committee (IRC) assessment. The primary endpoint was assessed in the tumour response evaluable set, which comprised all treated patients with a measurable lesion at baseline and at least one adequate scheduled post-baseline tumour assessment or the presence of radiological disease progression, with a sensitivity analysis done in the full analysis set, which comprised all patients who received at least one dose of savolitinib. Safety was also evaluated in the full analysis set. This study is registered with ClinicalTrials.gov, NCT02897479, and recruitment is complete, with treatment and follow-up ongoing. FINDINGS: From Nov 8, 2016, to Aug 3, 2020, 84 patients with METex14 skipping alterations were screened for eligibility, of whom 70 were enrolled, received savolitinib, and comprised the full analysis set. The IRC-assessed tumour response evaluable set comprised 61 patients. At a median follow-up of 17·6 months (IQR 14·2-24·4), the IRC-assessed objective response rate was 49·2% (36·1-62·3; 30 of 61 patients) in the tumour response evaluable set and 42·9% (95% CI 31·1-55·3; 30 of 70 patients) in the full analysis set. All 70 patients reported at least one treatment-related adverse event. Treatment-related adverse events of grade 3 or more occurred in 32 (46%) patients, the most frequent of which were increased aspartate aminotransferase (n=9), increased alanine aminotransferase (n=7), and peripheral oedema (n=6). Treatment-related serious adverse events occurred in 17 (24%) patients, the most common being abnormal hepatic function (n=3) and hypersensitivity (n=2). One death due to tumour lysis syndrome in a patient with pulmonary sarcomatoid carcinoma was assessed to be probably related to savolitinib by the investigator. INTERPRETATION: Savolitinib yielded promising activity and had an acceptable safety profile in patients with pulmonary sarcomatoid carcinoma and other NSCLC subtypes positive for METex14 skipping alterations. Savolitinib could therefore be a novel treatment option in this population. FUNDING: Hutchison MediPharma and AstraZeneca. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Lu S, Fang J, Li X, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respir Med. 2021. PMID: 34166627. doi:10.1016/S2213-2600(21)00084-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。